

All letters are subject to editing and may be shortened. General letters can be sent to bjgpdisc@rcgp.org.uk (please include your postal address for publication), and letters responding directly to *BJGP* articles can be submitted online via **eLetters**. We regret we cannot notify authors regarding publication. For submission instructions visit: <http://www.bjgp.org/letters>

Diagnostic biopsy of melanoma: primary or secondary care?

Murchie *et al*¹ compared morbidity and mortality in patients who had initial diagnostic excision biopsy in primary versus secondary care. The Breslow thickness of a melanoma is the main prognostic indicator in the melanoma patients included in this study. The mean thickness in both the primary and secondary care groups was ≤ 1 mm: such patients have a 95% 10-year survival rate,² so that mortality and morbidity are not particularly relevant endpoints.

Suspected melanoma is best managed in secondary care because meeting a patient at their initial clinic visit and diagnostic biopsy allows a more informed discussion at the MDT, leading to better management, and if the melanoma is diagnosed in secondary care, we can ensure that 'breaking of bad news' is made by a clinician or skin cancer support nurse, who have the knowledge and experience to explain the prognostic significance of the melanoma, the MDT decisions and the further treatments required.

We have looked at patients who had GP melanoma excisions in our region. In 70% of cases no clinical diagnosis was given on the pathology form, which may affect the interpretation of the pathology and the speed with which the material is processed. To improve lesion recognition and management by GPs in our region, GPs are invited to sit in on our weekly rapid access tumour clinics. We also plan to distribute a bi-monthly presentation of 'lesion pictures' to all GPs. A 'minor surgery interest group' has been formed who will meet annually to improve lesion recognition and management and to promote regional skin cancer pathways and communication between GPs and the local skin cancer team. We advise that suspicious pigmented lesions are referred urgently to secondary care. We hope our education programme will improve the experience of the patient, the GP and the secondary care physician involved in management of skin cancer patients.

M Mowbray,

Consultant Dermatologist, Queen Margaret Hospital, Dunfermline.

Jinah Yoo,

Dermatology Registrar, Lauriston Building, Edinburgh.

E-mail: Jinah.Yoo@nhslothian.scot.nhs.uk

REFERENCES

1. Murchie P, Raja AE, Lee AJ, Campbell NC. Mortality and morbidity after initial diagnostic excision biopsy of cutaneous melanoma in primary versus secondary care. *Br J Gen Pract* 2013; doi:10.3399/bjgp13X670697
2. Balch CM, Gershenwald JE, Soong SJ, *et al.* 2009 AJCC Melanoma Classification and Staging. *J Clin Oncol* 2009; **27**(36): 6199–6206.

DOI: 10.3399/bjgp14X676302

Authors' response

We disagree with the correspondents' comment that, since the mean thickness in both the primary and secondary care groups was ≤ 1 mm, mortality and morbidity are not particularly relevant endpoints. We presented median and not mean values in our paper. In fact, over 40% of the lesions in each group of our study had a Breslow thickness ≥ 1 mm. Furthermore, patients can die from melanoma irrespective of the Breslow thickness of the primary lesion, so mortality was the most appropriate primary outcome for our study. Similarly, morbidity, in this case, subsequent hospital attendances, must be included in any analysis where questions of surgical competence are being addressed.

We salute the excellent model of care that the corresponders are advocating, and implementing. However, they do not appear to provide any evidence as to why high quality skin biopsy of suspicious pigmented lesions in primary care could not be incorporated. We re-assert our conclusion that our study clearly signifies the need for a randomised controlled trial to establish the role of initial excision biopsy in primary care in the diagnosis and treatment of cutaneous melanoma in the UK. In the long run, this may be beneficial for both patients and the NHS.

Peter Murchie,

Division of Applied Health Science, University of Aberdeen, Aberdeen.

E-mail: p.murchie@abdn.ac.uk

E Amalraj Raja, Amanda J Lee, Neil C Campbell

Division of Applied Health Science, University of Aberdeen, Aberdeen.

DOI: 10.3399/bjgp14X676311

The future of elderly care in Turkey

Although elderly and end-of-life care have been neglected in Turkey, because older people did not constitute a high percentage of the population, the proportion of citizens aged >65 years is now 7.5%, with this proportion expected to increase to 10.2% by 2023, 21% by 2050 and 28% by 2075.¹ These estimates put Turkey as one of the most rapidly ageing populations in the world and have stimulated research and discussions around healthy ageing, chronic disease management and elderly care.

Turkey has also started to observe and analyse how other countries have managed this situation. Advance care planning has also been a topic of discussion for the older population. The UK has been one of the countries that have put efforts into better care of older people, and recent publications in the *BJGP* have inspired us.^{2,3}

The family medicine model has been fully implemented in Turkey since 2010. The new model allows doctors to have their own registered patients and the most reliable data in Turkey relies on the medical records of these registries. The opportunity here lies in the recognition of the transitions in people's lives, as described by Eynon *et al.*³ The unique relation of GPs with their patients and the enthusiasm of the new model facilitates communication and gives time to speak on the topics that were not previously touched.

When is the right time to discuss advance care planning? We think that earlier is better, when people are still healthy and can make sound decisions. For a population still young, but ageing very rapidly as in Turkey, discussions around advanced directives have already been started.⁴ Such a move is likely to overcome the challenges Sharp *et al.* mention, such as families, time, patient reluctance, or dementia.²

It is not easy to talk on these topics. The fear and discomfort experienced by the GP might